Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| So, we're very encouraged that our treating physicians, our principal investigators, are very eager to get patients into the study |
| We saw an encouraging response signal at the initial dose of 1x 10^6 CAR T cells per kilogram with two of the three patients achieving complete metabolic response and the third achieving a partial response as of the December 4 cutoff date |
| And we were able to keep those costs down very significantly compared to what the original forecast looked like |
| We continue to be excited about the potential of ONCT-534 and its novel mechanism of action, which may address a significant unmet need for advanced prostate cancer patients who progress after currently approved AR pathway inhibitor therapy and before they move into more aggressive treatment options such as chemotherapy or radioligand therapy |
| So, we're optimistic that it's not going to take too long |
| We believe these changes will help us further ensure patient safety as we investigate the optimal dose of ONCT-808 for patients with advanced B-cell lymphoma, including patients who have relapsed after CD19 CAR T treatment |
| We are excited to be advancing the clinical development of novel pathways in areas with very high unmet medical need, specifically patients with metastatic castrate-resistant prostate cancer harboring androgen receptor mutations and splice variants and patients with aggressive B-cell lymphoma who are relapse, refractory or unable to obtain CD19 CAR T therapy |
| Overall, our two clinical programs, ONCT-534 and ONCT-808, are advancing, and we are looking forward to potential significant value inflection points for the Company from both programs in the near term |
| Great |
| Carl Byrnes Congratulations on your progress |
| We continue to advance our two clinical programs towards significant clinical data inflection points by midyear, while reiterating our cash runway guidance into 2025 |
| So of course, progress of clinical trials is difficult to predict with accuracy, but we are hopeful that we'll be able to -- we'll be speaking about both the 160-milligram dose and the 300-milligram dose at the -- by the end of the second quarter |
| And so, as you can imagine, with that kind of an indication, there's a multibillion dollar potential |
| That's fine |
| Thank you, Jim |
| With respect to upcoming milestones, we remain on track |
| And we do believe that there is a potential for a sales potential of $1 billion or near $1 billion |
| Statement |
|---|
| Net loss for the fourth quarter was $9.2 million, or a loss of $3.11 per share, basic and diluted |
| For the full year, our net loss was $39.5 million, or a loss of $13.43 per share, basic and diluted |
| And then last question is just looking at your OpEx burn, Rich, you came in a pretty decent bit, 10% below what we were expecting |
| Common adverse events in this dosing cohort included decreased blood counts, pneumonia, and Grade 1-2 cytokine release syndrome, or CRS |
| But just what are the reasons that your R&D was -- it seems to be almost $1 million less than what we were expecting |
| Our actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with our business |
| The first patient treated at the dose level of 3x10^6 CAR T cells per kilogram, an 80-year-old with bulky disease who had received 4 previous lines of therapy, including CD19 CAR T, experienced a fatal serious adverse event consistent with CRS and immunofactor cell-associated neurotoxicity syndrome |
Please consider a small donation if you think this website provides you with relevant information